Overview

Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission

Status:
Terminated

Trial end date:
2017-05-30

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if ixazomib can prevent AML or MDS from coming back in patients who are in remission. The safety of this drug will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Millennium: The Takeda Oncology Company

Treatments:

Glycine
Ixazomib